Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silo Pharma filings document a Nasdaq-listed Nevada operating company with common stock registered under symbol SILO and a developmental-stage biopharmaceutical business. Its registration statements and offering-related disclosures address registered securities, capital structure, smaller reporting company status, and securities transactions associated with a company developing CNS, psychiatric and chronic-pain therapeutic programs.
Recent 8-K and proxy filings record material agreements, equity issuances, shareholder voting matters, board and compensation-plan actions, and governance changes. Disclosures also cover asset purchases for QwikAgents and cryptocurrency-related software, formation of a cryptocurrency advisory board, registered and private securities transactions, and the amendment of the company’s 2020 omnibus equity incentive plan.
Silo Pharma, Inc. has implemented a 1-for-15 reverse stock split of its common stock, reclassifying every 15 issued and outstanding shares into one share with the same par value.
At the same time, the company proportionately reduced its authorized common stock to 6,666,667 shares. The reverse split became effective on June 2, 2026, with split-adjusted trading on Nasdaq beginning June 3, 2026 under the existing symbol SILO and a new CUSIP. Outstanding options, warrants, and equity plan reserves were adjusted proportionately, and fractional shares were rounded up to the next whole share. Existing registration statements on Forms S-1 and S-3 are automatically amended so that the amount of shares covered is reduced in line with the 1-for-15 ratio under Rule 416(b).
Silo Pharma is implementing a 1-for-15 reverse stock split of its common stock, with a concurrent proportional cut in authorized shares. The split becomes effective as of 4:01 p.m. Eastern Time on June 2, 2026, and shares will begin trading on a post-split basis on June 3, 2026 under the same symbol, SILO.
Every 15 pre-split shares will be exchanged for 1 post-split share, with fractional positions rounded up to the next whole share. The company expects issued and outstanding shares to decrease from approximately 16.267 million to about 1.084 million. Authorized common stock will be adjusted to 6,666,667 shares, and the share amounts and exercise prices for equity awards, warrants, and plan reserves will be adjusted proportionately.
Silo Pharma reported a Q1 2026 net loss of $1,647,117, wider than a year earlier, as it increased spending on research and development and recorded losses on its cryptocurrency holdings. Revenue remained minimal at $18,026 from license fees, underscoring its early-stage status.
Cash and cash equivalents were $3,902,514 with short-term investments of $2,129,659, supporting working capital of $6,098,849 as of March 31, 2026. Management states this liquidity is sufficient to meet obligations for at least twelve months, easing prior going-concern concerns.
The company advanced its biopharmaceutical pipeline while diversifying, forming AI-focused subsidiary Qwikagentsai and purchasing AI software and domains for $714,000 in stock, all expensed as R&D. It also recorded an impairment of $29,911 on staked crypto assets and unrealized crypto losses, reflecting volatility in its digital asset treasury strategy.
Silo Pharma, Inc. is registering up to 5,023,340 shares of common stock underlying Series A-1 warrants, Series A-2 warrants and placement agent warrants.
The prospectus offers common stock purchase warrants exercisable upon issuance at an exercise price of $0.60 per share; Series A-1 warrants expire five years from the Initial Exercise Date and Series A-2 warrants expire eighteen months from the Initial Exercise Date. The offering price per common stock purchase warrant is $0.60. The company states it will receive proceeds only upon cash exercise of the warrants and may receive up to approximately $3.0 million if all warrants are exercised at the stated price. The company discloses Nasdaq minimum bid-price noncompliance and a second compliance period extending to June 22, 2026, and lists operating losses and cash balances in its historical consolidated financial data.
Silo Pharma, Inc. is registering up to 820,911 shares of common stock issuable upon the exercise of certain warrants.
The Shares consist of 763,638 shares issuable upon exercise of the July 2024 Investor Warrants at $2.75 per share and 57,273 shares issuable upon exercise of the July 2024 Placement Agent Warrants at $3.4375 per share. Upon cash exercise of all Warrants the company would receive aggregate gross proceeds of approximately $2.3 million. The registration covers resale by the Selling Shareholders; the company will not receive proceeds from resale transactions.
Shares outstanding would be 17,087,504 assuming full exercise of the Warrants; Nasdaq minimum-bid noncompliance and remediation periods are disclosed.
Silo Pharma, Inc. files a Post-Effective Amendment to its Form S-1 registering up to 5,023,340 shares of common stock underlying common stock purchase warrants and placement agent warrants.
The amendment re-states the offering of 2,416,670 Series A-1 warrants, 2,356,670 Series A-2 warrants and up to 250,000 placement agent warrants, each warrant tied to an underlying common share and priced at a public offering price of $0.60 per combined unit. The Company states it will receive proceeds only if warrants are exercised, estimated at approximately $3.0 million if all warrants are cashed in at the stated exercise price. The filing also incorporates the Company’s Form 10-K for the year ended December 31, 2025 and updates disclosure including Nasdaq minimum bid-price noncompliance and related cure period.
Silo Pharma, Inc. amends its Form S-1 to register for resale up to 820,911 shares of common stock issuable upon exercise of outstanding warrants. The registration covers (i) 763,638 shares from July 2024 investor warrants at an exercise price of $2.75 and (ii) 57,273 placement agent warrant shares at $3.4375. The company states it would receive up to approximately $2.3 million if all warrants are cash-exercised. The selling shareholders may sell from time to time; the company will not receive resale proceeds. Shares outstanding were reported as 17,087,504 assuming full exercise. The filing notes Nasdaq minimum bid-price noncompliance procedures with an extended compliance period through June 22, 2026.
Silo Pharma, Inc. entered into an asset purchase agreement to acquire the software for the QwikAgents web-based application and related domain names from Many Ads Inc. In exchange for these assets, Silo issued 2,100,000 shares of its common stock to the seller.
The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo for issues such as misrepresentations, software infringement, and specified misconduct. The shares were issued in a private, unregistered transaction relying on a securities law exemption.